<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031456</url>
  </required_header>
  <id_info>
    <org_study_id>PRP- POI</org_study_id>
    <nct_id>NCT04031456</nct_id>
  </id_info>
  <brief_title>Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients</brief_title>
  <acronym>PRP</acronym>
  <official_title>Investigating Reactivation of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in POI Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genesis Athens Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genesis Athens Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autologous PRP intra ovarian infusion may restore ovarian function, may promote&#xD;
      folliculogenesis and may improve patients' hormonal profile in patients presenting with POI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This triple-blind Randomized Controlled Trial (RCT) aims to investigate the effectiveness of&#xD;
      autologous PRP intra ovarian infusion on reactivating ovarian functionality and on promoting&#xD;
      folliculogenesis in regard to patients presenting with POI. PRP is blood plasma prepared from&#xD;
      fresh whole blood that has been enriched with platelets. It is collected from peripheral&#xD;
      veins and contains several growth factors such as vascular endothelial growth factor (VEGF),&#xD;
      epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth&#xD;
      factor (TGF) and other cytokines all of which stimulate tissue proliferation and growth. PRP&#xD;
      has been employed in several medical conditions in Orthopedics, Dermatology, and&#xD;
      Ophthalmology for wound healing. It's efficacy in ovarian rejuvenation and reactivation and&#xD;
      endometrial regeneration has not been fully elucidated. This study aims to investigate the&#xD;
      effect of autologous PRP intra ovarian infusion on restoring ovarian tissue functionality in&#xD;
      POI patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restoration of menstrual cycle</measure>
    <time_frame>Three months</time_frame>
    <description>Regular menstrual cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum FSH levels</measure>
    <time_frame>Follow-up period of three months entailing monthly evaluation</time_frame>
    <description>Serum FSH levels evaluated monthly for three consecutive months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum AMH levels</measure>
    <time_frame>Follow-up period of three months entailing monthly evaluation</time_frame>
    <description>Serum ΑΜΗ levels evaluated monthly for three consecutive months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LH levels</measure>
    <time_frame>Follow-up period of three months entailing monthly evaluation</time_frame>
    <description>Serum LH levels evaluated monthly for three consecutive months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Estradiol levels</measure>
    <time_frame>Follow-up period of three months entailing monthly evaluation</time_frame>
    <description>Serum estradiol levels evaluated monthly for three consecutive months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Progesteron levels</measure>
    <time_frame>Follow-up period of three months entailing monthly evaluation</time_frame>
    <description>Serum progesterone levels evaluated monthly for three consecutive months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antral Follicle Count (AFC)</measure>
    <time_frame>Follow-up period of three months entailing monthly evaluation</time_frame>
    <description>AFC evaluated monthly, on day 2 of the menstrual cycle, for three consecutive months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Menopause, Premature</condition>
  <condition>Menopause Related Conditions</condition>
  <condition>Menopausal Syndrome</condition>
  <condition>Premature Ovarian Failure</condition>
  <condition>Ovarian Failure, Premature</condition>
  <arm_group>
    <arm_group_label>Participants receiving PRP treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women presenting with POI, 25-39 years of age, treated with autologous PRP intra ovarian infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receiving Platelet Free Plasma (PFP) treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women presenting with POI, 25-39 years of age, treated with autologous PFP intra ovarian infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Platelet Rich Plasma</intervention_name>
    <description>Autologous PRP intra ovarian infusion</description>
    <arm_group_label>Participants receiving PRP treatment</arm_group_label>
    <other_name>PRP</other_name>
    <other_name>Platelet Rich Plasma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo-Platelet Free Plasma</intervention_name>
    <description>Autologous PFP intra ovarian infusion</description>
    <arm_group_label>Participants receiving Platelet Free Plasma (PFP) treatment</arm_group_label>
    <other_name>PFP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 40 years, presenting with amenorrhea or menstrual cycle irregularities for at&#xD;
             least four months, and elevated FSH levels &gt;25 IU/L recorded on two occasions &gt;4 weeks&#xD;
             apart&#xD;
&#xD;
          -  Normal Karyotype: 46, XX&#xD;
&#xD;
          -  Discontinuation of any complementary/adjuvant treatment including hormone replacement,&#xD;
             acupuncture, and botanotherapy, for at least three months prior to recruitment.&#xD;
&#xD;
          -  Willing to comply with study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any pathological disorder related to reproductive system anatomy&#xD;
&#xD;
          -  AMH &gt; 8 pmol/L&#xD;
&#xD;
          -  Endometriosis&#xD;
&#xD;
          -  Adenomyosis&#xD;
&#xD;
          -  Fibroids and adhesions&#xD;
&#xD;
          -  Infections in reproductive system&#xD;
&#xD;
          -  Current or previous diagnosis of cancer in reproductive system&#xD;
&#xD;
          -  History of familiar cancer in reproductive system&#xD;
&#xD;
          -  Severe male factor infertility&#xD;
&#xD;
          -  Prior referral for PGT&#xD;
&#xD;
          -  Ovarian inaccessibility&#xD;
&#xD;
          -  Endocrinological disorders (Hypothalamus-Pituitary disorders, thyroid dysfunction,&#xD;
             diabetes mellitus, metabolic syndrome)&#xD;
&#xD;
          -  BMI&gt;30 kg/m2 or BMI&lt;18.5 kg/m2&#xD;
&#xD;
          -  Systematic autoimmune disorders&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mara Simopoulou, PhD</last_name>
    <phone>+306979234100</phone>
    <email>marasimopoulou@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agni Pantou, MD, PhD Candidate</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Genesis AC</name>
      <address>
        <city>Athens</city>
        <zip>15232</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mara Simopoulou, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Agni Pantou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Konstantinos Pantos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

